Ana Alcaraz-Sanabria

TL;DR: A synthetic lethality interaction between CHEK1 and AURKA inhibitors with potential translation to the clinical setting is identified by using an in silico approach and is linked with detrimental outcome in patients.

TL;DR: Gene expression analyses demonstrated that the BET inhibitor JQ1 reduced the expression of kinases involved in cell division, and synergized with Volasertib in a panel of triple negative cell lines, demonstrating the synergistic interaction between BET and PLK inhibitors.

TL;DR: Genes linked to cell cycle control are associated with worse outcome in early stage ovarian cancer and incorporation of these biomarkers in clinical studies may help in the identification of patients at high risk of relapse for whom optimizing adjuvant therapeutic strategies is needed.

TL;DR: It is found that the combined expression of IFNG, CD30, CXCL13, and PRF1 correlated with better overall survival (OS) in advanced stage ovarian cancer and predicted for better prognosis in ovarian tumors with low mutational load.

TL;DR: WGCNA identifies relevant gene modules related to biological functions that can influence survival and be targeted pharmacologically and observed that genes in some of these modules were associated with clinical outcome and/or represented druggable opportunities, including AURKA, AURKB, PLK 1, MCM2, CDK1, YWHAE, HSP90AB1, LCK, or those targeting ubiquitination.